Upstate Active Clinical Trials

Study Title:

A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus (T2DM)

What is the purpose of the study?

The purpose of this study is to evaluate the effectiveness of insulin glargine/lixisenatide combination as compared with insulin glargine alone and with lixisenatide alone. The three treatments are self-injected once daily.

Upstate Institutional Review Board (IRB) Number:

566461

Study/Protocol ID:

EFC12404

Study Phase:

3

Patient Age Group:

Adults

Principal Investigator:

Ruth S Weinstock, MD, PhD

What is involved if I participate?

  • How long is the study?
    37 Weeks
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Procedures during study visits include: physical exams, vital signs, blood collection, urinalysis, ECG, questionnaire completion. Subjects will be asked to keep a diary of blood glucose readings throughout the study.

Where will the study take place?

Clinical Research Unit at IHP (505 Irving Ave.)

Other Information:

Study medications in pen form will be provided for the length of the study, along with a glucose meter and testing supplies

ClinicalTrials.Gov ID:

NCT02058147

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Jane D Bulger
Phone: 315-464-9008
Email: bulgerj@upstate.edu

Return to Previous Page || Search Again